Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib vs Tocilizumab in Severe COVID-19
NCT05082714Completed
- Sponsor
- University General Hospital of Patras
- Start
- Oct 2021
- Primary completion
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of baricitinib in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University General Hospital of Patras. Primary endpoint: Mechanical ventilation or death by day 28. Started Oct 2021; status: completed.
02
Drugs
baricitinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05082714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05082714.